Ann: December 2023 Preclinical & Clinical Program Update, page-66

Great question. The simple answer is low for a number of reasons.

1. RC220 has now been used in four different animal species at doses far higher than we ever intend to use in humans and no peripheral vein infusion (PVI) issues have been observed.

2. RC220 has passed all the accepted non-clinical models for PVI. These are all designed to be a good model of humans.

3. Bisantrene was successfully infused into humans via a peripheral vein in historical trials. What they did was dilute Bisantrene down to a very low concentration and infuse it slowly over 72 hours so the infusion rate was below the level that caused precipitation (crystallisation) in the vein. The veins were exposed to Bisantrene for 3 days without any issue.

RC220 would still have great value for RAC even if it could only be given via a central line as it extends the patent life from 2034 to well into 2044. Those extra 10 years are worth a lot.

Thanks for your support.